The New England Journal of Medicine publishes results of fidaxomicin Phase III trial showing significantly lower recurrence rates and improved global cure rates compared to vancomycin in patients with Clostridium difficile Infection (CDI).

Optimer Pharmaceuticals Inc has announced that The New England Journal of Medicine has published results from the North American Phase III trial evaluating the safety and efficacy of the company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase III trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the US Food and Drug Administration for CDI. The article titled, 'Fidaxomicin versus Vancomycin for Clostridium difficile Infection,' has appeared in the 3 Feb 2011 issue of The New England Journal of Medicine. Data …